Labmate UK & Ireland

Hope for a new treatment for bone cancer
The Bone Cancer Research Trust has funded a new project at the University of Nottingham, which is testing a theory that ‘friendly bacteria’ can be used to kill bone cancer cells. Researchers at the School of Clinical Sciences’ Division of Pre-Clinical Oncology are investigating whether modifying a harmless type of the bacterium, Salmonella typhimurium, can produce molecules which kill cancer cells in osteosarcoma, a primary bone cancer. The scientists are using a clinically safe form of the bacterium which has been found to localise to tumour tissue rather than healthy tissue.

Leading the research, Dr Teresa Coughlan, said: “Developing a treatment that effectively targets cancer cells, but doesn’t damage healthy cells is the Holy Grail for bone cancer treatment. We are excited by this project as potentially it could result in a new treatment for osteosarcoma, which typically has a poor prognosis.”

A main challenge in developing better treatments for bone cancer is finding a much more effective way of targeting anticancer drugs at the tumour. Many drugs are given by intravenous injection and use the body’s venous system to reach their target, but tumours in bone tend to have a low blood supply.

Dr Coughlan’s aim is to modify the Salmonella bacteria to act as a vehicle for cancer-killing agents. It’s believed special molecules, called RNA interference molecules, when produced in the bacteria will be more effectively released into malignant cells destroying the levels of cancer-causing molecules there.

Technical Articles

• Nuclear Magnetic Resonance Technology Improves Sample Throughput
• Compliance, Risk and Cost of Ownership Comparisons for Critical Laboratory and Facility Continuous Monitoring - Wired, Wireless and Standalone Systems

Spotlight Features

• Food & Beverage Analysis
• Sample Preparation & Processing

Special Features

• Research & Event News
• News & Views
• New Literature & Products
• Marketplace